Mitchell T Seman, Shawn H Malan, Matthew R Buras, Richard J Butterfield, Kristi L Harold, James A Madura, David M Rosenfeld, Andrew W Gorlin
{"title":"低剂量氯胺酮输注治疗腹腔镜胃旁路手术患者围手术期疼痛:一项前瞻性随机对照试验。","authors":"Mitchell T Seman, Shawn H Malan, Matthew R Buras, Richard J Butterfield, Kristi L Harold, James A Madura, David M Rosenfeld, Andrew W Gorlin","doi":"10.1155/2021/5520517","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Obesity is a common comorbidity seen in the perioperative setting and is associated with many diseases including cardiovascular disease and obstructive sleep apnea. Laparoscopic Roux-en-Y gastric bypass is the gold standard surgical treatment for patients whose weight is refractory to diet and exercise. Caring for these patients perioperatively presents unique challenges to anesthesiologists and is associated with an increased risk of adverse respiratory events. In our study, we hypothesize that a low-dose perioperative ketamine infusion will reduce opioid consumption and improve analgesia when compared to standard therapy.</p><p><strong>Methods: </strong>This is a single-center, prospective randomized controlled study enrolling 35 patients in total. Patients were randomized equally into the ketamine and control group. Preop, intraop, and postop management regimens were standardized. The ketamine group received a 0.3 mg/kg ideal body weight ketamine bolus after induction followed by a 0.2 mg/kg/hr ketamine infusion continued into the postop setting for up to 24 hours. Data collected included total perioperative opioids used converted to oral morphine equivalents (ME), pain scores, side effects, hospital length of stay, and patient satisfaction captured via postoperative questionnaires.</p><p><strong>Results: </strong>The use of perioperative opioid consumption was significantly lower in the ketamine group when compared with the control group (179.9 ME versus 248.7 ME, <i>P</i>=0.03). There was no statistically significant difference in pain scores or hospital length of stay postoperatively between the two groups. There were also no reported adverse respiratory events, prolonged sedation, agitation, or other side effects reported in either group. The patient satisfaction questionnaires showed a significant difference with the ketamine group reporting lower maximum pain scores, a decrease in how pain limited activities of daily living once discharged, and increased hospital pain management satisfaction scores.</p><p><strong>Conclusions: </strong>Perioperative low-dose ketamine infusions significantly reduced opioid consumption in morbidly obese patients undergoing laparoscopic gastric bypass surgery.</p>","PeriodicalId":7834,"journal":{"name":"Anesthesiology Research and Practice","volume":"2021 ","pages":"5520517"},"PeriodicalIF":1.6000,"publicationDate":"2021-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321702/pdf/","citationCount":"6","resultStr":"{\"title\":\"Low-Dose Ketamine Infusion for Perioperative Pain Management in Patients Undergoing Laparoscopic Gastric Bypass: A Prospective Randomized Controlled Trial.\",\"authors\":\"Mitchell T Seman, Shawn H Malan, Matthew R Buras, Richard J Butterfield, Kristi L Harold, James A Madura, David M Rosenfeld, Andrew W Gorlin\",\"doi\":\"10.1155/2021/5520517\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Obesity is a common comorbidity seen in the perioperative setting and is associated with many diseases including cardiovascular disease and obstructive sleep apnea. Laparoscopic Roux-en-Y gastric bypass is the gold standard surgical treatment for patients whose weight is refractory to diet and exercise. Caring for these patients perioperatively presents unique challenges to anesthesiologists and is associated with an increased risk of adverse respiratory events. In our study, we hypothesize that a low-dose perioperative ketamine infusion will reduce opioid consumption and improve analgesia when compared to standard therapy.</p><p><strong>Methods: </strong>This is a single-center, prospective randomized controlled study enrolling 35 patients in total. Patients were randomized equally into the ketamine and control group. Preop, intraop, and postop management regimens were standardized. The ketamine group received a 0.3 mg/kg ideal body weight ketamine bolus after induction followed by a 0.2 mg/kg/hr ketamine infusion continued into the postop setting for up to 24 hours. Data collected included total perioperative opioids used converted to oral morphine equivalents (ME), pain scores, side effects, hospital length of stay, and patient satisfaction captured via postoperative questionnaires.</p><p><strong>Results: </strong>The use of perioperative opioid consumption was significantly lower in the ketamine group when compared with the control group (179.9 ME versus 248.7 ME, <i>P</i>=0.03). There was no statistically significant difference in pain scores or hospital length of stay postoperatively between the two groups. There were also no reported adverse respiratory events, prolonged sedation, agitation, or other side effects reported in either group. The patient satisfaction questionnaires showed a significant difference with the ketamine group reporting lower maximum pain scores, a decrease in how pain limited activities of daily living once discharged, and increased hospital pain management satisfaction scores.</p><p><strong>Conclusions: </strong>Perioperative low-dose ketamine infusions significantly reduced opioid consumption in morbidly obese patients undergoing laparoscopic gastric bypass surgery.</p>\",\"PeriodicalId\":7834,\"journal\":{\"name\":\"Anesthesiology Research and Practice\",\"volume\":\"2021 \",\"pages\":\"5520517\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2021-07-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321702/pdf/\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anesthesiology Research and Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2021/5520517\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ANESTHESIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anesthesiology Research and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2021/5520517","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 6
摘要
肥胖是围手术期常见的合并症,与心血管疾病和阻塞性睡眠呼吸暂停等多种疾病有关。腹腔镜Roux-en-Y胃旁路手术是饮食和运动对体重难以耐受的患者的金标准手术治疗。围手术期护理这些患者对麻醉师提出了独特的挑战,并与不良呼吸事件的风险增加有关。在我们的研究中,我们假设与标准治疗相比,低剂量的围手术期氯胺酮输注可以减少阿片类药物的消耗并改善镇痛。方法:这是一项单中心、前瞻性随机对照研究,共纳入35例患者。患者随机分为氯胺酮组和对照组。术前、术中、术后管理方案标准化。氯胺酮组在诱导后给予0.3 mg/kg理想体重氯胺酮丸,随后0.2 mg/kg/hr氯胺酮输注,持续至停药后24小时。收集的数据包括围手术期使用的阿片类药物转化为口服吗啡当量(ME)、疼痛评分、副作用、住院时间以及通过术后问卷获取的患者满意度。结果:氯胺酮组围手术期阿片类药物使用量明显低于对照组(179.9 ME vs 248.7 ME, P=0.03)。两组患者的疼痛评分和术后住院时间均无统计学差异。两组均无不良呼吸事件、长时间镇静、躁动或其他副作用的报告。患者满意度问卷显示,氯胺酮组报告的最大疼痛评分较低,出院后疼痛限制日常生活活动的程度降低,医院疼痛管理满意度评分较高。结论:围手术期低剂量氯胺酮输注可显著减少接受腹腔镜胃旁路手术的病态肥胖患者的阿片类药物消耗。
Low-Dose Ketamine Infusion for Perioperative Pain Management in Patients Undergoing Laparoscopic Gastric Bypass: A Prospective Randomized Controlled Trial.
Introduction: Obesity is a common comorbidity seen in the perioperative setting and is associated with many diseases including cardiovascular disease and obstructive sleep apnea. Laparoscopic Roux-en-Y gastric bypass is the gold standard surgical treatment for patients whose weight is refractory to diet and exercise. Caring for these patients perioperatively presents unique challenges to anesthesiologists and is associated with an increased risk of adverse respiratory events. In our study, we hypothesize that a low-dose perioperative ketamine infusion will reduce opioid consumption and improve analgesia when compared to standard therapy.
Methods: This is a single-center, prospective randomized controlled study enrolling 35 patients in total. Patients were randomized equally into the ketamine and control group. Preop, intraop, and postop management regimens were standardized. The ketamine group received a 0.3 mg/kg ideal body weight ketamine bolus after induction followed by a 0.2 mg/kg/hr ketamine infusion continued into the postop setting for up to 24 hours. Data collected included total perioperative opioids used converted to oral morphine equivalents (ME), pain scores, side effects, hospital length of stay, and patient satisfaction captured via postoperative questionnaires.
Results: The use of perioperative opioid consumption was significantly lower in the ketamine group when compared with the control group (179.9 ME versus 248.7 ME, P=0.03). There was no statistically significant difference in pain scores or hospital length of stay postoperatively between the two groups. There were also no reported adverse respiratory events, prolonged sedation, agitation, or other side effects reported in either group. The patient satisfaction questionnaires showed a significant difference with the ketamine group reporting lower maximum pain scores, a decrease in how pain limited activities of daily living once discharged, and increased hospital pain management satisfaction scores.